Who is sponsoring NCT01473732?

NCT01473732 is sponsored by Montefiore Medical Center.

What condition does NCT01473732 study?

NCT01473732 studies Chronic Allograft Injury, Calcineurin Inhibitor Toxicity.

What drugs are being tested in NCT01473732?

Interventions: Everolimus, Tacrolimus, Mycophenolic acid.

What is the status of NCT01473732?

NCT01473732 is currently TERMINATED.

Last reviewed 2018-09-17 · How we verify

Mechanisms and Treatment of Chronic Allograft Injury (CAI) Due to Calcineurin Inhibitor (CNI) Toxicity

NCT01473732 NA TERMINATED Results posted

The purpose of this study is to find out how well the current drug regimen (including low Prograf dose and Myfortic, which is usually recommended to prevent any further deterioration in the kidney function) works and how safe it is when compared to a combination of Zortress and Myfortic in patients with chronic kidney injury associated with Prograf or Neoral use.

Details

Lead sponsor	Montefiore Medical Center
Phase	NA
Status	TERMINATED
Enrolment	2
Start date	2012-03
Completion	2012-08

Conditions

Chronic Allograft Injury
Calcineurin Inhibitor Toxicity

Interventions

Everolimus
Tacrolimus
Mycophenolic acid

Primary outcomes

Change in eGFR (Creatinine Clearance) as Measured by Serum Creatinine Blood Test — Baseline, One year
Estimated glomerular filtration rate (eGFR) indicates kidney function. Normal eGFR value for healthy is 80-120ml/min. For transplants, it is expected to be 60-80 ml/min.

Countries

United States